UBS Group’s Ambrx Biopharma Inc AMAM Stock Holding History

UBS Group’s Portfolio AMAM Stock Details AMAM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-3,840	Closed	-$54.7K	–	10337
2023 Q4	$54.7K	Sell	3,840 -1,734	-31%	-$19.7K	﹤0.01%	6488
2023 Q3	$64.1K	Buy	+5,574	New	+$75.9K	﹤0.01%	6125
2023 Q2	–	Sell	-56,868	Closed	-$715K	–	10015
2023 Q1	$507K	Buy	56,868 +53,824	+1,768%	+$270K	﹤0.01%	4678
2022 Q4	$6.91K	Sell	3,044 -4,923	-62%	-$5.63K	﹤0.01%	8966
2022 Q3	$9K	Buy	7,967 +7,725	+3,192%	+$15.9K	﹤0.01%	8627
2022 Q2	$1K	Buy	+242	New	+$923	﹤0.01%	10055

UBS Group's AMAM Position: Q1 2024 in Review

UBS Group sold out of Ambrx Biopharma Inc (AMAM) in Q1 2024, closing a stake of 3,840 shares — an estimated $54.7K sold.

UBS Group first reported a position in AMAM in Q2 2022 and held it in 6 quarters. The position peaked at $507K in Q1 2023. 0 funds tracked by Wall St. Rank hold AMAM as of Q1 2024.

UBS Group reported no remaining Ambrx Biopharma Inc position as of Q1 2024 after selling out during the quarter.
UBS Group sold 3,840 Ambrx Biopharma Inc shares in Q1 2024, an estimated $54.7K.
UBS Group first reported a position in Ambrx Biopharma Inc in Q2 2022 and held it in 6 quarters.
UBS Group's Ambrx Biopharma Inc position peaked at $507K in Q1 2023.
0 funds tracked by Wall St. Rank held Ambrx Biopharma Inc as of Q1 2024.

Based on UBS Group's 13F filing for Q1 2024, filed 13 May 2024.